文献速递类风湿关节炎

类风湿关节炎患者接种疫苗后抗S IgG水平可预测24周内抗SARS-CoV-2中和活性

Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA.
PubMed 文献 · RMD Open · 2022-01-01

RECOVER前瞻性单中心研究纳入类风湿关节炎(RA)患者与健康对照,评估两剂mRNA抗SARS-CoV-2疫苗接种后免疫应答。RA患者IgG应答较慢且峰值较低,但抗S IgG水平与12周和24周时强中和活性显著相关,或可识别需额外疫苗剂量或预防方案的患者。

要点

  • RA患者接种两剂mRNA疫苗后IgG应答较健康对照延迟且峰值滴度较低。
  • 接种后12周,73例RA患者中60.3%检出强中和活性,21例健康对照全部检出。
  • 第二剂后2周抗S IgG水平与12周和24周强中和活性显著相关。

核心结论

  • RA患者疫苗诱导的IgG抗体水平降低,而IgA和IgM应答持续存在,提示同种型转换延迟。
  • 第二剂后2周抗S IgG水平与12周和24周强中和活性的产生相关,或可识别可能受益于额外疫苗剂量或预防方案的患者。

研究设计与样本

  • RECOVER研究为前瞻性单中心研究,纳入类风湿关节炎患者和健康对照。
  • 评估时间点为第一剂疫苗前及第一剂后3、6、12和24周,包括IgG、IgA和IgM应答(针对受体结合域、S1、S2、N)、IFN-γ酶联免疫斑点及中和试验。

主要发现

  • RA患者IgG应答较健康对照发展更慢且峰值滴度更低。
  • 接种后12周,SARS-CoV-2假病毒中和试验检出强中和活性:21例健康对照全部检出,73例RA患者中60.3%检出。
  • 第二剂后2周峰值抗S IgG水平与12周和24周强中和活性显著相关。
  • 针对不同病毒蛋白的IgG、IgA和IgM同种型应答分析显示IgG应答延迟,而IgA和IgM应答未见延迟。
  • T细胞应答在健康对照和RA患者中相当,但在RA患者中下降更早。

关键数值与推荐

  • 接种后12周强中和活性:健康对照21例中全部检出,RA患者73例中60.3%检出。
  • 第二剂后2周抗S IgG水平与12周和24周强中和活性显著相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To correlate immune responses following a two-dose regimen of mRNA anti-SARS-CoV-2 vaccines in patients with rheumatoid arthritis (RA) to the development of a potent neutralising antiviral activity. METHODS: The RECOVER study was a prospective, monocentric study including patients with RA and healthy controls (HCs). Assessments were performed before, and 3, 6, 12 and 24 weeks, after the first vaccine dose, respectively, and included IgG, IgA and IgM responses (against receptor binding domain, S1, S2, N), IFN-γ ELISpots as well as neutralisation assays. RESULTS: In patients with RA, IgG responses developed slower with lower peak titres compared with HC. Potent neutralising activity assessed by a SARS-CoV-2 pseudovirus neutralisation assay after 12 weeks was observed in all 21 HCs, and in 60.3% of 73 patients with RA. A significant correlation between peak anti-S IgG levels 2 weeks after the second vaccine dose and potent neutralising activity against SARS-CoV-2 was observed at weeks 12 and 24. The analysis of IgG, IgA and IgM isotype responses to different viral proteins demonstrated a delay in IgG but not in IgA and IgM responses. T cell responses were comparable in HC and patients with RA but declined earlier in patients with RA. CONCLUSION: In patients with RA, vaccine-induced IgG antibody levels were diminished, while IgA and IgM responses persisted, indicating a delayed isotype switch. Anti-S IgG levels 2 weeks after the second vaccine dose correlate with the development of a potent neutralising activity after 12 and 24 weeks and may allow to identify patients who might benefit from additional vaccine doses or prophylactic regimen.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Schmiedeberg K, Abela IA, Pikor NB, et al. Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA. RMD Open. 2022. PMID: 36288822. doi:10.1136/rmdopen-2022-002575

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。